637 related articles for article (PubMed ID: 24440087)
21. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
22. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
23. Constitutional mismatch repair deficiency in a healthy child: On the spot diagnosis?
Suerink M; Potjer TP; Versluijs AB; Ten Broeke SW; Tops CM; Wimmer K; Nielsen M
Clin Genet; 2018 Jan; 93(1):134-137. PubMed ID: 28503822
[TBL] [Abstract][Full Text] [Related]
24. Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD).
Ramchander NC; Ryan NA; Crosbie EJ; Evans DG
BMC Med Genet; 2017 Apr; 18(1):40. PubMed ID: 28381238
[TBL] [Abstract][Full Text] [Related]
25. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers.
Goel A; Nagasaka T; Hamelin R; Boland CR
PLoS One; 2010 Feb; 5(2):e9393. PubMed ID: 20195377
[TBL] [Abstract][Full Text] [Related]
26. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
27. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
28. [Recent advances and future development on Lynch syndrome-associated endometrial cancer].
Ning Y; Wang Y; Wang YY; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):505-8. PubMed ID: 24246913
[No Abstract] [Full Text] [Related]
29. Cancer and constitutional Mismatch Repair Deficiency syndrome due to homozygous MSH 6 mutation in children with Café au Lait Spots and review of literature.
Özyörük D; Cabı EÜ; Taçyıldız N; Pınarlı F; Erdoğan AO; Hanalioğlu Ş; Erdem AY; Demir AM
Turk J Pediatr; 2021; 63(5):893-902. PubMed ID: 34738371
[TBL] [Abstract][Full Text] [Related]
30. Interobserver variability in the evaluation of mismatch repair protein immunostaining.
Klarskov L; Ladelund S; Holck S; Roenlund K; Lindebjerg J; Elebro J; Halvarsson B; von Salomé J; Bernstein I; Nilbert M
Hum Pathol; 2010 Oct; 41(10):1387-96. PubMed ID: 20573374
[TBL] [Abstract][Full Text] [Related]
31. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies.
Poley JW; Wagner A; Hoogmans MM; Menko FH; Tops C; Kros JM; Reddingius RE; Meijers-Heijboer H; Kuipers EJ; Dinjens WN;
Cancer; 2007 Jun; 109(11):2349-56. PubMed ID: 17440981
[TBL] [Abstract][Full Text] [Related]
32. In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response.
Meijer TW; Hoogerbrugge N; Nagengast FM; Ligtenberg MJ; van Krieken JH
Histopathology; 2009 Oct; 55(4):414-22. PubMed ID: 19817892
[TBL] [Abstract][Full Text] [Related]
33. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.
González-Acosta M; Marín F; Puliafito B; Bonifaci N; Fernández A; Navarro M; Salvador H; Balaguer F; Iglesias S; Velasco A; Grau Garces E; Moreno V; Gonzalez-Granado LI; Guerra-García P; Ayala R; Florkin B; Kratz C; Ripperger T; Rosenbaum T; Januszkiewicz-Lewandowska D; Azizi AA; Ragab I; Nathrath M; Pander HJ; Lobitz S; Suerink M; Dahan K; Imschweiler T; Demirsoy U; Brunet J; Lázaro C; Rueda D; Wimmer K; Capellá G; Pineda M
J Med Genet; 2020 Apr; 57(4):269-273. PubMed ID: 31494577
[TBL] [Abstract][Full Text] [Related]
34. PMS2 involvement in patients suspected of Lynch syndrome.
Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
[TBL] [Abstract][Full Text] [Related]
35. Improved survival with an intact DNA mismatch repair system in endometrial cancer.
Cohn DE; Frankel WL; Resnick KE; Zanagnolo VL; Copeland LJ; Hampel H; Kelbick N; Morrison CD; Fowler JM
Obstet Gynecol; 2006 Nov; 108(5):1208-15. PubMed ID: 17077244
[TBL] [Abstract][Full Text] [Related]
36. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1.
Wimmer K; Rosenbaum T; Messiaen L
Clin Genet; 2017 Apr; 91(4):507-519. PubMed ID: 27779754
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
[TBL] [Abstract][Full Text] [Related]
38. Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases.
Diniz G; Aktas S; Cubuk C; Ortac R; Vergin C; Olgun N
Pediatr Hematol Oncol; 2013 May; 30(4):273-84. PubMed ID: 23570624
[TBL] [Abstract][Full Text] [Related]
39. [Should we systematically screen for Lynch syndrome in patients with upper urinary tract carcinoma?].
Olagui GS; Pignot G; Rouquette A; Vieillefond A; Amsellem-Ouazana D; de Longchamps NB; Radenen B; Zerbib M; Terris B
Bull Cancer; 2014 Feb; 101(2):144-50. PubMed ID: 24556207
[TBL] [Abstract][Full Text] [Related]
40. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1.
Krüger S; Kinzel M; Walldorf C; Gottschling S; Bier A; Tinschert S; von Stackelberg A; Henn W; Görgens H; Boue S; Kölble K; Büttner R; Schackert HK
Eur J Hum Genet; 2008 Jan; 16(1):62-72. PubMed ID: 17851451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
